Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Applied Nutrition flags full-year results ahead of expectations

(Sharecast News) - Applied Nutrition said in an update on Tuesday that it expects full-year results to come in ahead of market expectations, with revenue and profit both posting strong double-digit growth. The London-listed sports nutrition, health and wellness group reported that revenue for the year ended 31 July rose 24% to about £107m, compared with £86m a year earlier, while adjusted EBITDA increased by around 19% from £26m.

Net cash at the year-end was also stronger than expected at about £18.5m, ahead of the £16.6m consensus forecast.

The company said the performance was driven by a strong second half, which contributed around £60m of sales, underpinned by its global growth strategy.

Looking ahead, Applied Nutrition said it expected revenue for the 2026 financial year to be above current consensus, which previously stood at £112.4m.

The firm said it remained confident that its B2B-focused model, broad product range and investment in new product development would continue to support growth and profitability.

"We are proud to report that we have exceeded the guidance we gave at our IPO, with our first full-year results expected to come in ahead of market expectations," said chief executive Thomas Ryder.

"Our focus and ambition remain as strong as ever - in delivering for our shareholders, customers and team - and we are excited about the opportunities we have in the pipeline for the year ahead."

The company said it expects to publish its full results on or around 10 November.

At 0931 BST, shares in Applied Nutrition were up 8.41% at 142.24p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.